邵薪诺,曲连卉,李光辉,涂应锋

• 1:哈尔滨医科大学附属第一医院心血管内科

摘要(Abstract)：

隐源性脑卒中占缺血性脑卒中的25%，且病情更严重，死亡率、致残率及复发率均较高，造成沉重的临床负担。卵圆孔未闭与隐源性脑卒中的关系已被证实，并于2020年正式确立“卵圆孔未闭相关性脑卒中”这一概念。卵圆孔未闭作为隐源性脑卒中的主要致病原因，因具有隐蔽性、反复性特征，现已经成为心血管内科与神经内科亟需解决的临床问题。矛盾栓塞被认为是卵圆孔未闭相关性脑卒中的主要发病机制，但原位血栓、房性心脏病及循环物质蓄积证据的出现颠覆了传统认知。此外，目前对卵圆孔未闭相关性脑卒中的防治尚缺乏统一的认识，因此，本文将对卵圆孔未闭相关性脑卒中的发病机制及治疗的最新研究进展进行综述，为明确卵圆孔未闭相关性脑卒中的发病机制及寻找潜在治疗靶点提供新思路，以更好指导临床做好卵圆孔未闭相关性脑卒中的防治工作。

关键词(KeyWords)： 卵圆孔未闭;原位血栓;房性心脏病;隐源性脑卒中

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81671746、81871402）;; 黑龙江省博士后科学基金项目（LBH-Q19037）

作者(Author): 邵薪诺,曲连卉,李光辉,涂应锋

参考文献(References)：

• [1] Maloku A,Hamadanchi A,Franz M,et al. Patent foramen ovale—when to close and how?[J]. Herz, 2021,46(5):445-451. DOI:10.1007/s00059-021-05061-y.
• [2] Baik M, Shim CY, Gwak SY, et al. Patent foramen ovale and risk of recurrence in stroke of determined etiology[J]. Ann Neurol, 2022,92(4):596-606. DOI:10.1002/ana.26449.
• [3] Ahmad Y, Howard JP, Arnold A, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke:a metaanalysis of randomized controlled trials[J]. Eur Heart J,2018,39(18):1638-1649. DOI:10.1093/eurheartj/ehy121.
• [4] Yan C, Li H. Preliminary investigation of in situ thrombus within patent foramen ovale in patients with and without stroke[J].JAMA, 2021, 325(20):2116-2118. DOI:10.1001/jama.2021.4359.
• [5] Kasner SE, Lattanzi S, Fonseca AC, et al. Uncertainties and controversies in the management of ischemic stroke and transient ischemic attack patients with patent foramen ovale[J].Stroke, 2021, 52(12):e806-e819. DOI:10.1161/STROKEAHA.121.034778.
• [6] Yan C, Li H, Wang C, et al. Frequency and size of in situ thrombus within patent foramen ovale[J]. Stroke, 2023,54(5):1205-1213.DOI:10.1161/STROKEAHA.122.041524.
• [7] Deng W,Mc Mullin D,Inglessis-Azuaje I,et al. Ef fect of patent foramen ovale closure after stroke on circulatory biomarkers[J].Neurology, 2021,97(2):e203-e214.DOI:10.1212/WNL.0000000000012188.
• [8] Huber C, Wachter R, Pelz J, et al. Current challenges and future directions in handling stroke patients with patent foramen ovale-a brief review[J]. Front Neurol, 2022,13:855656.DOI:10.3389/fneur.2022.855656.
• [9] Mac Grory B, Ohman EM, Feng W, et al. Advances in the management of cardioembolic stroke associated with patent foramen ovale[J]. BMJ, 2022,376:e063161.DOI:10.1136/bmj-2020-063161.
• [10] Liu K, Song B, Palacios IF, et al. Patent foramen ovale attributable cryptogenic embolism with thrombophilia has higher risk for recurrence and responds to closure[J]. JACC Cardiovasc Interv,2020, 13(23):2745-2752. DOI:10.1016/j.jcin.2020.09.059.
• [11] Liu X, Zhang Y, Xie H, et al. Change in patent foramen ovale height is associated with cryptogenic stroke and the construction of a morphology-based scoring system[J]. Front Cardiovasc Med, 2022,9:1010947.DOI:10.3389/fcvm.2022.1010947.
• [12] Chino S, Mochizuki Y, Mizuma K, et al. Transcranial doppler for stratifi cation of high-risk morphology of patent foramen ovale in patients with cryptogenic stroke[J]. Heart Vessels, 2022,37(12):2119-2127. DOI:10.1007/s00380-022-02117-9.
• [13] Hindricks G, Potpara T, Dagres N, et al. Corrigendum to:2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC[J]. Eur Heart J, 2021,42(40):4194. DOI:10.1093/eurheartj/ehab648.
• [14] Rigatelli G, Zuin M, Roncon L. Increased blood residence time as markers of high-risk patent foramen ovale[J]. Transl Stroke Res,2023, 14(3):304-310. DOI:10.1007/s12975-022-01045-0.
• [15] Ning Y, Tse G, Luo G, et al. Atrial cardiomyopathy:an emerging cause of the embolic stroke of undetermined source[J].Front Cardiovasc Med, 2021,8:674612. DOI:10.3389/fcvm.2021.674612.
• [16] Leventis IA, Sagris D, Strambo D, et al. Atrial cardiopathy and likely pathogenic patent foramen ovale in embolic stroke of undetermined source[J]. Thromb Haemost, 2021,121(3):361-365. DOI:10.1055/s-0040-1715831.
• [17] Sardana M, Lessard D, Tsao CW, et al. Association o f l e f t atrial function index with atrial fibrillation and cardiovascular disease:the framingham offspring study[J].J Am Heart Assoc, 2018,7(7):e008435. DOI:10.1161/JAHA.117.008435.
• [18] Rigatelli G, Zuin M, Adami A, et al. Left atrial enlargement as a maker of signifi cant high-risk patent foramen ovale[J]. Int J Cardiovasc Imaging, 2019,35(11):2049-2056. DOI:10.1007/s10554-019-01666-x.
• [19] Leifer D,Rundek T. Atrial cardiopathy:a new cause for stroke?[J]. Neurology, 2019,92(4):155-156. DOI:10.1212/WNL.0000000000006749.
• [20] Silvestry FE, Cohen MS, Armsby LB, et al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale:from the American Society of Echocardiography and Society for Cardiac Angiography and Interventions[J].J Am Soc Echocardiogr,2015,28(8):910-958.DOI:10.1016/j.echo.2015.05.015.
• [21] Ueno Y. Editorial commentary:atrial septal aneurysm as a risk factor for ischemic stroke with patent foramen ovale[J]. Trends Cardiovasc Med, 2023, 33(6):334-335. DOI:10.1016/j.tcm.2022.05.003.
• [22] Mas JL, Saver JL, Kasner SE, et al. Association of atrial septal aneurysm and shunt size with stroke recurrence and benefi t from patent foramen ovale closure[J]. JAMA Neurol, 2022,79(11):1175-1179. DOI:10.1001/jamaneurol.2022.3248.
• [23]汪小君，蒋桔泉.房间隔膨出瘤的临床意义及治疗进展[J].中国心血管病研究，2023,21(1):78-82. DOI:10.3969/j.issn.1672-5301.2023.01.015.
• [24] Xu L, Zhou C, Pan X, et al. Effect of ASA on the risk of cerebrovascular ischemic events in patients with PFO[J].Ann Clin Transl Neurol, 2022,9(9):1384-1391. DOI:10.1002/acn3.51638.
• [25] Rigatelli G, Zuin M, Bilato C. Atrial septal aneurysm contribution to the risk of cryptogenic stroke in patients with patent foramen ovale:a brief updated systematic review and Meta-analysis[J]. Trends Cardiovasc Med, 2023, 33(6):329-333. DOI:10.1016/j.tcm.2022.02.006.
• [26] O’Suilleabhain P. Yet another way to lower homocysteine:close the patent foramen ovale[J]. Neurology, 2021,97(2):55-56. DOI:10.1212/WNL.0000000000012194.
• [27] Li Y, Lu J, Wang J, et al. Inflammatory cytokines and risk of ischemic stroke:a mendelian randomization study[J].Front Pharmacol, 2022,12:779899. DOI:10.3389/fphar.2021.779899.
• [28] Wu Z, Zhang C, Liu N, et al. A nomogram for predicting patent foramen ovale-related stroke recurrence[J]. Front Neurol,2022,13:903789. DOI:10.3389/fneur.2022.903789.
• [29] Li Y, Xia B, Li R, et al. Expression of brain-derived neurotrophic factors, neurotrophin-3, and neurotrophin-4 in the nucleus accumbens during heroin dependency and withdrawal[J].Neuroreport, 2017,28(11):654-660.DOI:10.1097/WNR.0000000000000810.
• [30] Acampa M, Lazzerini PE, Guideri F, et al. Infl ammation and atrial electrical remodelling in patients with embolic strokes of undetermined source[J]. Heart Lung Circ, 2019,28(6):917-922. DOI:10.1016/j.hlc.2018.04.294.
• [31]郭慧敏，胡海波.卵圆孔未闭可能诱发脑脑卒中相关生化指标的研究进展[J].中国介入心脏病学杂志，2023,31(2):138-141. DOI:10.3969/j.issn.1004-8812.2023.02.009.
• [32] Karakus A, Okutucu S. High eosinophil rates in patients with right-to-left shunts:an expected role, or an unexpected risk?[J]. Cureus, 2021,13(1):e12849. DOI:10.7759/cureus.12849.
• [33]杨璐，周慧，沈文，等.先天性卵圆孔未闭相关缺血性卒中患者血清生化及全血细胞计数临床研究[J].中国介入心脏病学杂志，2022,30(10):770-774. DOI:10.3969/j.issn.1004-8812.2022.10.008.
• [34] Bridges ND, Hellenbrand W, Latson L, et al.Transcatheter closure of patent foramen ovale after presumed paradoxical embolism[J]. Circulation, 1992, 86(6):1902-1908.DOI:10.1161/01.cir.86.6.1902.
• [35] Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism[J]. N Engl J Med, 2013,368(12):1083-1091. DOI:10.1056/NEJMoa1211716.
• [36] S?ndergaard L, Kasner S E, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J].N Engl J Med, 2017,377(11):1033-1042. DOI:10.1056/NEJMoa1707404.
• [37] Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke[J].N Engl J Med, 2013,368(12):1092-1100. DOI:10.1056/NEJMoa1301440.
• [38] Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale:the DEFENSE-PFO trial[J].J Am Coll Cardiol, 2018,71(20):2335-2342. DOI:10.1016/j.jacc.2018.02.046.
• [39] Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J].N Engl J Med, 2017,377(11):1022-1032. DOI:10.1056/NEJMoa1610057.
• [40] Kasner SE, Rhodes JF, Andersen G, et al. Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke[J].N Engl J Med, 2021,384(10):970-971.DOI:10.1056/NEJMc2033779.
• [41] Mir H, Siemieniuk R, Ge L, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke:a systematic review and network Meta-analysis incorporating complementary external evidence[J]. BMJ Open, 2018,8(7):e23761.DOI:10.1136/bmjopen-2018-023761.
• [42] Cai Q, Ahmad M. Eustachian valve, interatrial shunt,and paradoxical embolism[J]. Echocardiography, 2020,37(6):939-944. DOI:10.1111/echo.14682.